Axsome Therapeutics Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $23.5M | $20.0M | $21.2M | $6.8M | $4.3M |
| SG&A Expense | $9.4M | $7.2M | $6.3M | $2.4M | $1.4M |
| Operating Income | $-32.8M | $-27.2M | $-27.5M | $-9.2M | $-5.7M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | — | — |
| Net Income | $-31.0M | $-28.9M | $-27.2M | $-12.2M | $-6.0M |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | $-1.15 | $-1.27 | $-1.42 | $-1.02 | $-0.66 |
| EPS (Diluted) | $-1.15 | $-1.27 | $-1.42 | $-1.02 | $-0.66 |
| Shares Outstanding (Basic) | 30.1M | 25.5M | 19.1M | 19.1M | — |
| Shares Outstanding (Diluted) | 30.1M | 25.5M | 19.1M | 19.1M | — |
| Dividends Per Share | — | — | — | — | — |